[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Eosinophilic Esophagitis (EoE) pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 79 pages | ID: E1BE5949B749EN
VPAResearch

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Eosinophilic Esophagitis (EoE) PIPELINE HIGHLIGHTS
Eosinophilic Esophagitis (EoE) is one of the widely researched conditions during 2020 with 18 companies actively focusing on realizing pipeline’s potential. Development of Eosinophilic Esophagitis (EoE) medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Eosinophilic Esophagitis (EoE) market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Eosinophilic Esophagitis (EoE).

Good progress is anticipated during 2020 and 2021 with Eosinophilic Esophagitis (EoE) pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Eosinophilic Esophagitis (EoE) pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Eosinophilic Esophagitis (EoE) DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Eosinophilic Esophagitis (EoE) pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Eosinophilic Esophagitis (EoE) pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Eosinophilic Esophagitis (EoE) presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Eosinophilic Esophagitis (EoE) pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Eosinophilic Esophagitis (EoE) DRUG PROFILES
Eosinophilic Esophagitis (EoE) development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Eosinophilic Esophagitis (EoE) COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Eosinophilic Esophagitis (EoE) drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Eosinophilic Esophagitis (EoE). Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 18 Eosinophilic Esophagitis (EoE) companies including company overview, key snapshot, contact information, and their strategies on accelerating Eosinophilic Esophagitis (EoE) pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Adare Pharmaceuticals, Allakos Inc, Arena Pharmaceuticals Inc, Banner Life Sciences LLC, Bristol-Myers Squibb Co, Calypso Biotech SA, DBV Technologies, Dr Falk Pharma, EsoCap AG, GlaxoSmithKline Plc, Humanigen Inc, Kyowa Kirin Co Ltd, Quorum Innovations LLC, RAPT Therapeutics Inc, Receptos Inc, Regeneron Pharmaceuticals Inc, Suzhou Connect Biopharmaceuticals Ltd, Takeda Pharmaceutical Co Ltd

REASONS TO BUY
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Eosinophilic Esophagitis (EoE)
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO EOSINOPHILIC ESOPHAGITIS (EOE)

1.1 Eosinophilic Esophagitis (EoE)- Disease overview
1.2 Eosinophilic Esophagitis (EoE)- Market Size
1.3 Eosinophilic Esophagitis (EoE)- Companies Involved

2. EOSINOPHILIC ESOPHAGITIS (EOE) PIPELINE SNAPSHOT- 2020

2.1 Eosinophilic Esophagitis (EoE) Pipeline by Phase
2.2 Eosinophilic Esophagitis (EoE) Pipeline by Mechanism of Action
2.3 Eosinophilic Esophagitis (EoE) Pipeline by Route of Administration
2.4 Eosinophilic Esophagitis (EoE) Pipeline- New Molecular Entities
2.5 Eosinophilic Esophagitis (EoE) Pipeline- Orphan Drug Designation/ Special Designation

3. EOSINOPHILIC ESOPHAGITIS (EOE) DRUG PROFILES

3.1 Current Status
3.2 Eosinophilic Esophagitis (EoE) Drug Snapshot
3.3 Eosinophilic Esophagitis (EoE) Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Adare Pharmaceuticals Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.2 Allakos Inc Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.3 Arena Pharmaceuticals Inc Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.4 Banner Life Sciences LLC Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.5 Bristol-Myers Squibb Co Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.6 Calypso Biotech SA Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.7 DBV Technologies Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.8 Dr Falk Pharma Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.9 EsoCap AG Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.10 GlaxoSmithKline Plc Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.11 Humanigen Inc Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.12 Kyowa Kirin Co Ltd Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.13 Quorum Innovations LLC Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.14 RAPT Therapeutics Inc Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.15 Receptos Inc Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.16 Regeneron Pharmaceuticals Inc Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.17 Suzhou Connect Biopharmaceuticals Ltd Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials
4.18 Takeda Pharmaceutical Co Ltd Eosinophilic Esophagitis (EoE) Pipeline Insights and Clinical Trials

5. EOSINOPHILIC ESOPHAGITIS (EOE) MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information


More Publications